Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02NMO
|
||||
| Former ID |
DPR000047
|
||||
| Drug Name |
FR-79620
|
||||
| Synonyms |
3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Eating disorder; Obesity; Diabetes [ICD9: 250, 278, 307.5; ICD10:E08-E13, E66, F50] | Preclinical | [1] | ||
| Company |
Fujisawa
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H13N3
|
||||
| Canonical SMILES |
CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
|
||||
| InChI |
1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
|
||||
| InChIKey |
CAQAIFUDUGDPFB-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.